Patent Issued for Detecting esophageal disorders (USPTO 11104960)

摘要

2021 SEP 21 (NewsRx) - By a News Reporter-Staff News Editor at Disease Prevention Daily - According to news reporting originating from Alexandria, Virginia, by NewsRx journalists, a patent by the inventors Ahlquist, David A. (Rochester, MN, US), Allawi, Hatim T. (Middleton, Wl, US), Kisiel, John B. (Rochester, MN, US), Lidgard, Graham P. (Middleton, Wl, US), Mahoney, Douglas W. (Elgin, MN, US), Taylor, William R. (Lake City, MN, US), Yab, Tracy C. (Rochester, MN, US), filed on September 13, 2019, was published online on August 31, 2021. The assignee for this patent, patent number 11104960, is Exact Sciences Development Company LLC (Madison, Wisconsin, United States). Reporters obtained the following quote from the background information supplied by the inventors: "In Barrett's esophagus, healthy esophageal epithelium is replaced with metaplastic columnar cells-the result, it is believed, of damage from prolonged exposure of the esophagus to the refluxate of gastroesophageal reflux disease (GERD). The inherent risk of progression from Barrett esophagus to adenocarcinoma of the esophagus has been established. Histologically, this progression involves clear sequential stages from metaplasia alone to low grade dysplasia, then to high grade dysplasia, and finally to adenocarcinoma.